Devil's Claw (Herb/Suppl)

Brand and Other Names:afrikanische teufelskralle, ao ao, more...arpagofito, Arthrosetten H, Arthrotabsm, artiglio del diavolo, Artosan, Defencid, Doloteffin, duiwelsklou, ekatata, elyata, grapple plant, griffe du diable, Hariosen, Harpadol, HarpagoMega, harpagon, harpagophytum procumbens, harpagoside, Jucurba N, khams, khuripe, klaudoring, likakata, otjihangatene, RheumaSern, RheumaTee, Salus, sengaparile, Sudafrikanische Teufelskralle, Trampelklette, Venustorn, windhoek's root, wood spider, xemta'eisa
  • Print

Suggested Dosing

Osteoarthritis/Low Back Pain

Crude Extract: 2-9 g/d PO

Standardized Tablets: 600-1200 mg (=50-100 mg harpagoside) PO TID

Other Information

Anorexia: 1.5 g/day decoction

Elixir (1:1): 0.1-0.25 mL PO TID


Suggested Uses

Osteoarthritis, lower back pain, appetite loss, cancer pain


Increasing evidence of short-term benefit in osteoarthritis; some evidence of benefit in lower back pain; unclear with regards to other uses

Extensively used in Europe for mild joint pain

German Commission E approves the use of Devil's claw root for:

  • Appetite loss, dyspepsia, supportive therapy for arthritis

ESCOP approves the use of Devil's claw root for:

  • Painful arthrosis, tendinitis, appetite loss, dyspepsia


Interaction Checker

and Devil's Claw

No Results

     activity indicator 
    No Interactions Found
    Interactions Found


      Serious - Use Alternative

        Significant - Monitor Closely


            All Interactions Sort By:
             activity indicator 

            Adverse Effects

            Generally well-tolerated

            Headache, GI upset, bradycardia, taste loss




            Stomach or intestinal ulcer, diabetes, high or low blood pressure, arrhythmia

            Safety/efficacy not established for children


            Pregnancy & Lactation

            Pregnancy Category: N/A

            Lactation: N/A

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.



            Metabolism: N/A

            Excretion: N/A

            Mechanism of Action

            Unclear; one study found correlation between serum harpagoside levels & leukotriene biosynthesis inhibition; harpagoside may also have analgesic actions

            May also have anti-oxidant effects

            Constituents include iridoid glucosides (eg, harpagoside), phytosterols, & flavonoids

            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.